Clinical Trials Logo

ER Positive Breast Cancer clinical trials

View clinical trials related to ER Positive Breast Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04738292 Terminated - Metastatic Cancer Clinical Trials

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

A phase II single-arm trial of onapristone in combination with fulvestrant for women and men with ER-positive, PgR-positive or negative and HER2-negative locally advanced or metastatic breast cancer after progression on aromatase and CDK4/6 inhibitors. The study will enroll up to 39 participants.

NCT ID: NCT04504331 Terminated - Breast Cancer Clinical Trials

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Start date: October 13, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)

NCT ID: NCT02345772 Terminated - Clinical trials for HER2-positive Breast Cancer

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Neohttp
Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.